Q-omics provides the consensus-scored RBP1 profile across patient tissues and cancer cell-line models. RBP1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, RBP1 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, RBP1 protein abundance shows 18,914 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BLCA, HNSC, and LSCC as cancer lineages where RBP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBP1 survival associations across molecular data types. RBP1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBP1 RNA expression–survival associations across cancer types. High RBP1 expression shows unfavorable associations in BLCA, HNSC, LGG and KIRP, but favorable associations in ESCA and READ. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify BLCA as the clearest survival context for RBP1 RNA expression.
This table summarizes RBP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RBP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBP1 shows lower tumor expression in KIRP, KIRC and BLCA and higher tumor expression in HNSC, LUSC and COAD. The HNSC box plot shows higher RBP1 RNA expression in tumor versus normal tissue (log2 FC = +3.076, t-test p < 0.001).
This table shows molecular features associated with RBP1 in patient tissues and cancer cell lines. In patient samples, RBP1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RBP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and SOFT_TISSUE.
